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Drug resistanceAbstract The present cross-sectional study was conducted for the first time from the
Udupi district of coastal Karnataka to know the prevalence of drug resistance and
comparative analysis of MDR and non-MDR cases of pulmonary tuberculosis. Details
of 862 smear positive cases of pulmonary tuberculosis with age P15 years from 12
designated microscopy centres of the Udupi district were studied. Initially 2 sputum
samples trailed by one follow-up sample were collected from each patient and pro-
cessed for culture and drug sensitivity on the Lowenstein-Jensen medium. A total
resistance of 33.4% was observed that includes the mono-resistance of 22.5%,
multidrug resistance (MDR) of 6.3% and extensive drug resistance (XDR) of 0.3%. Sig-
nificant odds ratio (OR) was observed in category 2 cases (OR 3.9) for the develop-
ment of MDR tuberculosis. A significant statistical association was observed using
Fishers exact test while comparing mortality rate (19.3% vs. 1.8%), treatment fail-
ure (8.8% vs. 3.8%) and cure rate (68.4% vs. 85.4%) between MDR and non-MDR cases
(p < 0.001). Category 2 patients are important risk factors for the development of
MDR in pulmonary tuberculosis. Due to high mortality and low cure rate in MDR
276 P. Rao et al.cases it is imperative to know the drug sensitivity report before institution of
anti-tubercular treatment.
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) a disease caused by Mycobacteri-
um tuberculosis complex remains the cause of
highest mortality in humans, leading to three
million deaths annually, about five deaths every
minute [1]. Pulmonary tuberculosis (PTB), the
commonest form of TB is characterised by the
involvement of lung parenchyma resulting in
nodule formation in the lungs. India on an average
accounts for nearly 25% of the global burden
of tuberculosis and 29% of mortality due to
tuberculosis [1].
Although the phenomenon of drug resistance in
M. tuberculosis was observed as early as 50 years
ago, the spread of multi-drug resistant tuberculosis
(MDR) and emergence of extensively drug resistant
tuberculosis (XDR) is threatening to destabilize
global tuberculosis control [2]. India is also wit-
nessing an increase in the number of MDR cases
being reported from many parts of the country
[3,4]. An updated report from WHO in 2013 esti-
mated prevalence of 3.6% MDR tuberculosis in new-
ly diagnosed cases and 20% in previously treated
cases [5]. Though there is an increase in drug resis-
tance, testing for MDR status is done in very few
centres. Rowland has reported that fewer than 5%
of new or retreatment cases are tested for drug
sensitivity and an estimated 16% of the patients
with MDR tuberculosis are receiving inappropriate
treatment [6].
There are few well planned epidemiological
studies from the states of Tamil Nadu, Maharashtra
[7] and Gujarat [8]. However, studies available
from the referral hospitals of Karnataka [9,10]
show a much higher burden of MDR TB and it cannot
be extrapolated to the community. The knowledge
of drug resistance in PTB cases helps us to know the
exact burden of MDR status in this area and assists
in future to plan national control measures and the
treatment strategies in the case of pulmonary
tuberculosis.
Hence, a first community level study was under-
taken to study the prevalence of drug resistance,
comparison of MDR and non-MDR cases and to know
the outcomes of treatment in PTB patients of the
Udupi district in the south-western coastal area
of Karnataka.2. Methodology
2.1. Study settings
The cross-sectional study was carried out in the
Department of Microbiology of a tertiary care cen-
tre of south-west coastal Karnataka in liaison with
the district tuberculosis office during the period of
September 2011–August 2014. Ethical clearance
for the study was obtained from the institutional
ethics committee.
2.2. Sample collection
A total number of 990 cases of smear positive PTB
patients with ages P15 years from Designated
Microscopy Centres of the Udupi district (including
centres of three talukas and district tuberculosis
centre), Karnataka were included in the study.
Out of the 990 cases, cultures of samples from 28
cases had been contaminated, data could not be
collected completely for 33 cases who denied par-
ticipation, 37 cases were lost to follow up either
due to mortality or switching over to private treat-
ment and about 30 samples were culture negative
after eight weeks of incubation. Hence the data
for the remaining 862 cases as per the sample size
calculation are presented in the study. Two sputum
samples-one spot and one early morning sample
were initially collected from each patient and the
follow-up sample was collected after 3 months of
the anti-tuberculosis therapy (ATT). The HIV status
was determined for all the patients without failure
under the revised national tuberculosis control pro-
gramme with a spot test (Comb Aids, Span Diagnos-
tics, India). The demographic data of all the cases
were obtained by the interviewer through a pre-
designed questionnaire. No other forms of tubercu-
losis were evaluated in the study.
2.3. Sample processing
All the sputum samples were transported to our
lab in the cold chain. Decontamination and
concentration of the samples were done using the
modified Petroffs method [11]. Samples were
cultured on Lowenstein-Jensen media, incubated
for 4–8 weeks and the growth was confirmed with
the help of MPT 64 antigen detection kit as
Table 1 Drug susceptibility results of the total 862
cases.
Drug susceptibility pattern Numbers %
Pan sensitive 574 66.5
Total resistance 288 33.5
Monoresistance
Streptomycin (S) 144 16.7
Isoniazid (H) 40 4.4
Rifampicin (R) 7 1
Ethambutol (E) 3 0.3
Resistance to combination of drugs
S + H 24 2.8
S + R 5 0.6
S + E 3 0.3
R + E 4 0.5
S + H + E 1 0.1
MDR 54 6.3
XDR 3 0.3
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Diagnostics, Inc., Korea).
2.4. Drug sensitivity testing
First line drugs streptomycin (4 lg), isoniazid
(0.2 lg), rifampicin (40 lg), and ethambutol (2 lg)
and second line drugs capreomycin (40 lg), kanamy-
cin (30 lg), amikacin (40 lg), ofloxacin (2 lg), and
ethionamide (40 lg and 57 lg), were used for the
1% proportionate drug sensitivity testing as per the
WHO guidelines 2008 [12].
2.5. Statistical evaluation
All the cases were classified in two groups: MDR and
non-MDR. The association of demographical and
clinical parameters for these groups was analysed
using logistic regression. The prevalence of MDR
and outcomes of treatment are reported in
percentages with 95% confidence interval. The
treatment outcomes of MDR and non-MDR cases
were compared using Fishers exact test. Risk was
estimated using odds ratio (OR) with 95% confi-
dence interval (CI).
2.6. Important definitions
Category 1: Newly diagnosed case of PTB with no
history of previous treatment with ATT.
Category 2: Cases of PTB previously diagnosed and
treated with ATT includes failure/relapse/defaulter.
Taluka: It is an area of land with a city or town that
serves as its administrative centre, with possible
additional towns, and usually a number of villages.
Grey collar worker: Refers to people with occupations
like farming, other forms of agribusiness, fishing,
security, catering and skilled and semi-skilled labour.
MDR-TB: Resistance to two of the most important first
line drugs, isoniazid and rifampicin.
XDR-TB: Resistance to any one of the second line
injectable drugs along with fluoroquinolone in
addition to isoniazid and rifampicin.
3. Results
The recruited 862 cases of PTB had a male to
female ratio of 3:1 with 473 (54.9%) cases in the
age group of 15–45 years. There were 705 cases
in category 1 and 157 cases in category 2 with a
ratio of 4:1. Nearly 70% of the study population
belonged to the lower socio-economic status whose
family per capita income was less than INR 1600
per month. Monthly per capita income was calcu-
lated as per modified Kuppuswamys socioeconomic
scale for the year 2012 [13]. High proportion of thecases belonged to grey collar workers (60%)
followed by unskilled labourers (18%), house wives
(14%) and unemployed people (5%).
Commonest presenting symptoms of recruited
cases were cough in 858 (99.5%) followed by fever
in 725 (84%), weight loss in 666 (77.3%), chest pain
in 449 (52%) and haemoptysis in 74 (9%). Alcohol
consumption was noticed in 437 (51%) of the study
population, of whom about 420 (96%) were con-
suming more than 50 ml of alcohol per day. History
of smoking was present in 316 (37%) cases that
comprise nearly 172 (54.4%) cases that had 3–5
smoking pack years.
Nearly 167 (19.3%) cases had a history of previ-
ously diagnosed and treatment completion for
PTB and about 156 (18%) newly diagnosed cases
gave contact history with the TB patients within
or around the house hold.
Table 1 shows total resistance in 288 (33.5%)
cases of PTB, which includes the mono-resistance
in 194 (67.4%) and resistance to various combina-
tions of anti-tubercular drugs in 94 (32.6%) cases.
MDR in category 1 and 2 cases was observed in 32
(4.5%) and 25 (15.8%) respectively as shown in
Table 2.
Table 2 shows the association of demographic
and risk factors with MDR status. Significant odds
ratio was observed only in category 2 cases [OR
3.9, 95% CI – 2.26, 6.87] for the development of
MDR-TB using univariate regression. A multivariate
logistic regression model was done using para-
meters such as age, gender, socioeconomic status,
alcoholism, smoking and categorisation. The step
wise regression model identified category 2 as a
single predictor to be associated with MDR status
Table 2 Regression analysis of MDR and non-MDR cases of PTB in the study population.
Characteristics Total (862) (n, %) MDR (57) (n, %) Non MDR (805) (n, %) 95% CI for OR OR P value
Gender
Male 657 (76) 42 (6.4%) 615 (93.6%) (0.46, 1.59) 0.86 0.64
Female 205 (24) 15 (7.4%) 190 (92.6%)
Age (years)
15–30 201 (23.4) 17 (8.4%) 184 (91.6%)
31–45 272 (31.4) 17 (6.2%) 255 (93.8%) (0.35, 1.45) 0.72 0.36
>45 389 (45.1) 23 (5.9%) 366 (94.1%) (0.35, 1.30) 0.68 0.24
Category
Cat 1 705 (81.8) 32 (4.5%) 673 (95.5%)
Cat 2 157 (18.2) 25 (15.8%) 132 (84.2%) (2.26, 6.87) 3.9 <0.001
Per capita income (INR/mth)
<1600 600 (69.5) 35 (5.8%) 565 (94.2%) (0.06, 0.782) 0.20 0.02
1601–4800 248 (28.7) 19 (7.6%) 229 (92.4%) (0.07, 1.09) 0.27 0.06
>4801 14 (2) 3 (21%) 11 (79%)
Co-morbidities
Bronchial asthma 40 (4.6) 2 (5%) 38 (95%) (0.17, 3.12) 0.73 0.67
Diabetes 106 (12.3) 9 (8.5%) 97 (91.5%) (0.65, 2.87) 1.36 0.4
HIV co-infection 68 (8) 3 (4.4%) 65 (95.6%) (0.09, 1.70) 0.21 0.4
Smoking
Non smokers 546 (63) 41 (7.5%) 505 (92.5%)
Smokers 316 (37) 16 (5%) 300 (95%) (0.36, 1.19) 0.65 0.16
Alcoholism
Non alcoholics 425 (49) 38 (8.9%) 387 (99.1%)
Alcoholics 437 (51) 19 (4.3%) 418 (95.7%) (0.26, 0.81) 0.46 0.008
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Since only a single variable figured as a statistically
significant predictor of outcome in multivariate
model, the odds ratio remained the same as
univariate.
Cure rate of treatment among the MDR and
non-MDR cases was detected as 68.4% and 85.4%
respectively. Mortality was observed in 19.3% of
MDR cases including 2 out of 3 cases infected with
XDR-TB. However, one XDR-TB case was successfully
cured after treatment. The mortality in non-MDR
cases was noticed as 1.8% (Table 3).
Significant statistical association was observed
using Fishers exact test while comparing mortality
rate (19.3% vs. 1.8%), treatment failure (8.8% vs.Table 3 Analysis of treatment outcome of MDR and non-MDR
Outcomes Total
N (%)
N
N
Cured 718 (84.3) 6
Defaulter 35 (4.1) 3
Relapse 39 (4.6) 3
Treatment failure 35 (4.1) 3
Death 25 (2.9) 13.8%) and cure rate (68.4% vs. 85.4%) between
MDR and non-MDR cases (p < 0.001).
4. Discussion
The drug resistance in TB is the man-made prob-
lem, mainly due to inadequate treatment, default-
ing by the patient or poor quality of drugs.
Moreover, patients infected with MDR-TB need pro-
longed treatment with second line anti-tubercular
drugs. The present study is the first study from
the Udupi district of coastal Karnataka showing
the results of drug resistance in PTB cases. A total
resistance of 33.5% was observed in the study
population that includes 6.3% of MDR cases. Primarycases.
on-MDR
(%)
MDR
N (%)
P-value
79 (85.4) 39 (68.4)
3 (4.2) 2 (3.5)
9 (4.9) 0 <0.001
0 (3.8) 5 (8.8)
4 (1.8) 11 (19.3)
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tance of 15.8% were observed in the current study.
According to WHO data 2011 and TB India 2013, MDR
cases among notified PTB cases ranged from 3.6 to
6.2% that comprises newly diagnosed cases in the
range of 1.5–2.7% and retreatment cases up to
17% [14]. A surveillance study conducted in the state
of Gujarat by Ramachandran et al., found 2.4% of
MDR-TB in the newly diagnosed cases and 17.4% of
MDR-TB in previously treated cases [8]. Joseph
et al., from Kerala reported a MDR of 2% in newly
diagnosed cases [15]. Dutta et al. from Kashmir
reported an initial drug resistance of 5.4% and a sec-
ondary drug resistance of 36.5% among the study
population [4]. A small cohort study from Mangalore
by Bhat et al., reported a prevalence of 4% MDR-TB
in patients in 2010 [16].
Out of the 57 MDR-TB isolates in our study, 3
(5.2%) were XDR isolates. Thomas et al. from Chen-
nai in 2003 reported 1.5% XDR-TB isolates [17] and
Ramachandra et al. from Gujarat in 2006 reported
3.8% of the XDR isolates in the surveillance studies
[8]. On the contrary, Singh et al. [18] from New
Delhi in 2006 reported 33% and James et al. [19]
from Vellore in the year 2007 reported 60% of the
MDR isolates to be XDR. This high proportion of
XDR isolates can be explained as these two reports
are from tertiary care reference centres. Dutta
et al. from Kashmir in the year 2007 reported about
15.3% of the MDR-TB isolates in their study as
extensively drug resistant [4].
The present study has highlighted the association
of category 2 cases (OR 3.9) for the development of
MDR-TB. Previous treatment in TB is the strongest
risk factor which includes failed previous TB treat-
ment, relapsed after treatment or default during
previous treatment, for the development of MDR-
TB [20]. A study by Prasad et al. on the drug sensi-
tivity pattern of culture positive category 2 cases
reported nearly 58% had MDR tuberculosis [21].
Though the predisposition of a population having
type 2 diabetes mellitus (DM) with an odds of 1.5
and 1.7 for MDR-TB has been reported by Fisher–
Hoch et al. from Texas and Mexico [22], Subhash
from southern India did not see any association of
drug resistance with diagnosis or duration of
diabetes mellitus among the 26% MDR tuberculosis
cases [23] which also supports our study.
High proportion (85%) of cases in the study were
from lower socioeconomic groups like labourers,
unemployed and house wives with an index of
2 according to the modified Kuppuswamys socio-
economic status classification of 2012 with a mean
household of 5 members. Sethi et al., found that
nearly 70% of their study population belonged tothe lower socioeconomic group [24]. About 37% of
the cases reported smoking tobacco in our study.
Smoking is known to cause impaired clearance of
mucosal secretion, reduced phagocytic ability of
alveolar macrophages, and decrease in the immune
response and/or CD4 + lymphopenia due to the
nicotine in the cigarettes have been given as rea-
sons for increased susceptibility to PTB [25]. Nearly
51% of the cases self-reported to consume more
than 40 ml of alcohol upon questioning. A system-
atic review by Lonnroth et al., showed the relative
risk of 2.94 in pooled studies for the development
of tuberculosis where the subjects reported to con-
sume more than 40 ml of alcohol per day [26]. This
may be through direct toxic effects of alcohol on
the immune system, or indirectly through micro-
and macronutrient deficiency, or other alcohol-
related medical conditions such as malignancies
and depression. Jethani et al. on the contrary
reported 57% tobacco smoking and 35% of alco-
holism in their study population [27]. Although,
these risk factors have been proved to be
significant in the development of TB as seen in
the literature, we did not see any association of
these risk factors in the development of drug
resistant TB. But some studies by Gaude et al. from
Karnataka [10] and Fleming et al. from Russia [28]
have shown a significant association of (p < 0.05)
for alcoholism in development of drug resistance.
This may be explained due to not revealing their
alcoholic status by some of the studied population.
Other reasons may be due to high level of literacy
(86%) and public awareness which has resulted in
lesser percentage of population being addicted to
alcoholism and smoking compared to other parts
of Karnataka.
The study observed a higher rate of mortality
and treatment failure, but a low cure rate after
ATT in MDR cases as compared to non-MDR cases
(p < 0.001). Mortality was noticed in 19.3% MDR
cases (including XDR cases) against 1.8% in the
non-MDR tuberculosis cases. WHO global report of
2013, estimates an odds of 2.3 for mortality among
MDR-TB cases [5]. Among 3 XDR-TB infected cases,
mortality was 66.6%. ODonnell reported a
mortality of 42% among the XDR-TB infected cases
[29] and Gandhi NR in the South African region
reported a mortality rate of 80% among the
HIV co-infected population with XDR tuberculosis
[30].
5. Conclusions
Category 2 patients of PTB are at higher risk of
developing MDR-TB. Higher chances of treatment
280 P. Rao et al.failure, more mortality and less cure rate in MDR
cases necessitates the need for drug sensitivity
testing before institution of anti-tubercular treat-
ment. Appropriate therapeutic management can
help to reduce the spread of MDR strains.
6. Strengths of the study
This was the first community level study from our
tertiary care centre with public–private participa-
tion to determine the status of drug resistant PTB
in this region of the country. Our study supports
the national data of drug resistance in PTB for both
the categories.
With less number of defaulters, our study
highlights the awareness and effective therapeutic
management of the PTB cases by RNTCP in this part
of the country with a higher literacy level and
better access to medical facilities.
7. Limitations of the study
The study included only the population covered
under the DOTS programme. Part of the population
seeking private medical care is not included in the
study.
The study only concentrated on the smear posi-
tive PTB cases while smear negative PTB cases may
have been undiagnosed.
Lack of association between MDR-TB and risk
factors may be due to the failure to reveal the
habits of alcoholism and smoking, which explains
the social stigma attached with it leading to social
desirability bias.
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